N
Google TrendJONAS BROTHERS (500+) — Jonas Brothers postpone Birmingham concert over weather concerns
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:jonas brothers500+steven kwan500+kings vs warriors200+steffi graf200+boxing200+ben simmons500+lisa500+bill maher500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "BCMA/CD19 CAR T Shows Enc" (30 stories)

Top Headline Story

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
Lead StoryNaturegeneral
Mar 31

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3dXhHeFB5OVl1TndBX3kydWM1VDhUOUQzNjc2NlV3bUhxWURqakYxelhmYS1nZGdpWldOZDFwNVhXRnhRaFhvUmIwT1FPaUVvZldlOWtsOWpDUThqX2Zv?oc=5" target="_blank">Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+15m ago

jonas brothers

Jonas Brothers postpone Birmingham concert over weather concerns

Filter stories
500+15m ago

steven kwan

Guardians' Steven Kwan Could Shake Up Winter Outfield Market

Filter stories
200+15m ago

kings vs warriors

3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings

Filter stories
200+15m ago

steffi graf

PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance

Filter stories

Search Results for "BCMA/CD19 CAR T Shows Enc"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
Naturegeneral

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5lVXc1NVBUdFBONk5lOU8tcHpkQ3hBaFFvWU1ZQW9mQkNIbGZ6Zk9ZQWs4SzRzcFJyZ3dmXzBEc3VXdXk2Q0ZzMG13bUhCODJVMTFaT0c2cllxNGFseXhv?oc=5" target="_blank">Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon
Frontiersworld

CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOdVNpemYxMWNhUXkwaV9reHp2dmNpeVVHTkdRckFyTjhnRFd3RXJqYzV5TEk0V3hHUm9zTk44SFFNUVBxZmJUbENKSnZ1dlpMWDBlUWZMSkcyMnFRY0hRX25jc0p1V2U2Z1V4YWp5d0tyX3hkTE5tc2NsTVd5S1ZGWWk2cVFLMUVOUXZhZkJ0VjdNQQ?oc=5" target="_blank">CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Naturegeneral

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5JR2swMVRGSkVEUWJydXBHaTd4eFdoSEVfaHJtQm9YLTFyandEcGVtaFpJQjBiSWN2UDJlV3h0RXEzUXJfb0dUR2MyXzdtZ1RvUXBPLWIxNWxlZ0N2Tzl3?oc=5" target="_blank">BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells
Frontiersgeneral

eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxONnBfdUI5UGNUTEM3MVN5b0ZRb1o4czQwZ1BBb1kyU01KcEtzV1R1LUpSQUpldi1NSkI4SFZkMXRXOEx4Vkhib084ckVOVGE2Q05OSDlrbkxWX0VfUk4zN0hqR3JrR2d5NWdGMEllTVkxblBzdGFRakJYUUxfWmQ3cUxFVjJHMXN0Tm9VTGY2cGtCUQ?oc=5" target="_blank">eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Naturegeneral

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5OdnNmbGpyRzVielBNcGtjeWhPeVpIYzJkZHRtb3N0R1BJYlAxcjZxajN1cVN5YjlwTFNURkdaV2VnMUhtYW1NUU9oMzNkQjh5eGFxNTlwY2xhOVBxYjZF?oc=5" target="_blank">Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Frontiersgeneral

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPVy15aVdRSzZWLU5XclFEeUVrWkRDV21NS1RYT0NZRjlUcWxTSUxSQl9iRGJHekZvMUJicUNNaHg1RVhydDFrd0NyUktreGVGbkU0ZE56dGdlMENaX29ZTVFEMG5xMTJwOTNFZUg1aWxpS0U1b095VUdvTTVjTDgtRDVudmZFN1lPOTg0UXRxbzN1dw?oc=5" target="_blank">CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives
Frontiersworld

CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQQy1pNUYxMmN2QUdjT0xEaWJfaGZlT2Q2QVBuNmlzWlozaWtWb1NtVU02NEdrQzBpSHdQWWU4XzhXM3dnLUN0ZGhNelRYcVlZRm10VW9vUTRSTVRxR2NWd2NQUGJ5TVI0N053ZVdWeUdyTFRNYXBGU19UY3dkT3F3RzFmSGZRdjFkdVVacVIxLVNxZw?oc=5" target="_blank">CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
CAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal
Naturegeneral

CAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBpNVJMOWptcmpPV3BBRG5QeERCellyMl9DQ2JpZ2dMY0VqanNPVFBSeUdyWDRsc09EWUVzNS1KZE5qYm1weXlVNExuWU1JQ040SXE0NXBIeWxtOEdVTFRV?oc=5" target="_blank">CAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma
Naturegeneral

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xdmlXeU51eS12YVpZR0M0eWlpSnliMTVDV0VtemNVdEtUUnd2X1pIaXc4d3plWXNLb244aUpXek1jMUhZdlJpTGVTdHpjOFU1MUVkNWVrNHU0UE5XVUQ0?oc=5" target="_blank">Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
Naturegeneral

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5xakdudDBzSS1Sckc1MjV4MURQcUpROHQ3TkVVTTZmWFZ2VnJ4aDcwcWFEWHJSYUZHS3NLaE1RWks0V0RMWWQyZkNKYUZVVlpoTk1kVDItaVdJal9xMUlR?oc=5" target="_blank">Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Naturegeneral

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE94WERiYVB1MFdFQkVKU3dCNUdvcUZfbmU2eVFJdENFQWRhUkNNRW5pQ1lpWXN1YmhVc1FWbkw3TVQxRVJSYlhuMkU5MS16cE1QNVNuMGNPVUtsOWN6b2pB?oc=5" target="_blank">Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma | Leukemia
Naturegeneral

Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma | Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBNRXdObmV1Y19rejhxQTZmY1pMelhiRzJDRjd5YUJudXFDamc0enM3dXRyb2gwZWp2cW5tQjFMZHJtdGxOSGJNOTdLeWlMTWNtdWhjNXppZVo0Q3EwekVZ?oc=5" target="_blank">Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma | Leukemia</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy | Blood Cancer Journal
Naturegeneral

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5rdkRPdFQ3Tzl3bTJLci1sS0ZsVHZWNjllam1qaDE5NE9FMlE2U3M0RVJheURlNHhlTklvUkRCTENrVDZZdWoxQ2l4SHNwNUZTMTBqMERodjJiN0JoaFNB?oc=5" target="_blank">Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
Natureworld

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ReG1rMnNWWHlxaDFvRnFxZFFvQzRvbzJDTk8xOWUtRGNrS3ZobEdzR29MejZOdFFjQVRaMWtHYlYzUndQQzlUdkcyc0FuRjlLYUlKd3lKLVo2QmhGTmdN?oc=5" target="_blank">Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Naturegeneral

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBaLTdMZFBlQVVVR0tTZFNmalE2ZWRIN0x6NWhWMHp0R3cxT3FBZ2NtWWNrd3hiLUFIbk1Db2FHNHQyQjVwSkc1bGdYUm9DY1RmZnptbF90RnBwcjlqN2tF?oc=5" target="_blank">Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CAR T therapies in multiple myeloma: unleashing the future - Cancer Gene Therapy
Natureworld

CAR T therapies in multiple myeloma: unleashing the future - Cancer Gene Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBHVFBhSVM0dy1PVzFCVmdwNHN4LTZ2VEtHdkowZENKUVNpaXIyYWZsMFdsVWo0NXU5TGlDNU5WUEtrMlJSZThhaHR3Zm5IWVVVUlRDcXhtaVMzZFpodTVv?oc=5" target="_blank">CAR T therapies in multiple myeloma: unleashing the future - Cancer Gene Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously | Cancer Gene Therapy
Naturegeneral

An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously | Cancer Gene Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBmMm1RbXJldzVFZUZiNzNVTFZoM2ViSmJPQmpoRXJhYU1SYW1LMXVxZkJmbTN2Z0V4TEpieF9zQ3RvTXZTdmtJM3p0UlZzclJiajRsaFU3Vk1NRFNlQ3Vj?oc=5" target="_blank">An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously | Cancer Gene Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Naturegeneral

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBSZzExNTBJZzRUTWVkS3I2cjkzOXVBOXVvNzI0TnpWVzNFMjFaNzJ1cGRadkFma2p1N0RhUndVYXpYUkdpcmNHZU9EMlY2WVVaRGZka2dPazJfYjNVeWk4?oc=5" target="_blank">Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Long-term outcomes following CAR T cell therapy: what we know so far
Naturegeneral

Long-term outcomes following CAR T cell therapy: what we know so far

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1aRWlzV25laDFJakx2TGhTWEoyUjQ5NlJlamsxU3Z6NHVkTlVFV0dDaHRwRk5TTnNlNzltTkNENGU3M2ZiOFVUR2haSVE3ME1nT0dwOVU4QmNaWEJyd204?oc=5" target="_blank">Long-term outcomes following CAR T cell therapy: what we know so far</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility
Wiley Online Librarypolitics

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE00eWxZVkZZSXBDUFhHZ1A0ZE9hWG1VeFpJM1RNT2ZqbDgyVXNlaUF1WmJoUDdYb0pEREJ4b0VIUmJ3OXZzWkJNQ29yeTkyTFRiNC1vb2Q3R3UxUEdnUTJ3MC1qZEVOSnJQdFN3YVVn?oc=5" target="_blank">Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma | Leukemia
Naturegeneral

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma | Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9kUnNfUFJuRXJXV3JXREtXdmVzaGpDNWRMUG9YNXl3emMzT1pZNjFlckJ2aUN3Qm8wMGpnMDN1ZlFvXy1QcDFhSzFiMHpFMlU2b3NnblNVRVotYnJwbnNj?oc=5" target="_blank">Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma | Leukemia</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Naturegeneral

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5SaVFtVmxxOEhxRXZOUDNfMnpCOFBTSDZTYjkxcS1XeHNpSW0zUUQ5VnJxVzlhdzQwMzczQ2lGOWxrY0hlM09KNE9OOG9rOXNZV2Nac2lnNDFkSExSWHZV?oc=5" target="_blank">Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Frontiersworld

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNWmRYbDlEdEg4WktmQm50SHo2SVI5bFEwS3hfWTdabmtPdHVtVTJlNGNBUzZVcW1CNXdSbWZQLVFjZm1ZeVAtM19QaDdxNEN0bmZVVWRmTWFNRTktYXAwaThEaUcwZnNLam5TbnpES3NUXzBKMkFlTERMaEloNEdPR0ZsaGdHNHJWX3FXUGNlZw?oc=5" target="_blank">Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Science | AAASgeneral

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5qY3huZmNOZGdXbVNaczQ1dTYwa05jVFVUSGJydVJCY1VOVnZlVjYzeS1YYmQxS1VqeGN4WlI2ZVloamh5MzdYSmptajJMaENBZTNkRFlfRWFoT3ZKY1h3?oc=5" target="_blank">CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome</a>  <font color="#6f6f6f">Science | AAAS</font>

Read Full StoryMore like this
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
Naturegeneral

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBCcmZXam0zZHJYeEg4ZHdzUkhlVlBNVkU1dDdCWHRabDlUcHhqbDFnRXdWOEQ1ZDRCNjFQVS1YZXZqLWZaMENUZVFvZWtnTXhMYXB1c1NUSXBzWUJxSzEw?oc=5" target="_blank">Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma
Wiley Online Librarytech

Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE1TYVh5UUtnWWFnQUFMdUhwakhZaXFpMXZGek4wS01URGJzdkY1aEt3cFJsdDlsS1NYc1RBSWVBcUphWWZjS0VVTUZFdURWR0M2ZDgyRTQ2bk1EZmpSSzZLdTZDc1lac21SRXc?oc=5" target="_blank">Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk-benefit profile and response
Mayo Clinicgeneral

Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk-benefit profile and response

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPb3FuTDJxRjFXMDRDRlFfTFE4ZjY4YTh6cDNRdDhwRllLdFA3N1gzMkdDdDVFZVgtdUFsRlBpaUxfNldSZ2ZEMVZCNHJ1YURHbTVzOG8tRGJNRG1DYllueThRNExTSXFNSFJweUR3VnBFTndMbl84Umc1Q2dTNHl6WURFSFpQX0Q5enRTWlpDYXVBeVlMazd2N0FDaTVEUV9jZ2RBaWFkempGaDVkS1k5bHVLLVdjbUlVQjNLbU9Uck5zaHlwUUFkay05eUtwMWVjdVdHYjVmMGo3UjFZeEpCMWI4VUt5UDNpQTNscWswUjZ4bXZYU1hMOHFn?oc=5" target="_blank">Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk-benefit profile and response</a>  <font color="#6f6f6f">Mayo Clinic</font>

Read Full StoryMore like this
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels
Rockefeller University Presstech

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQMVh4SWZSb3FPOTNPajVRRml1QUpHbUJad0hDdVJqZGxqWjVMam9UTXhJRl8tRmtrVEt5UGF1TnR4WFFkY2I5ZUoyMFNRTGxLd3B4VUVPSGZTejVNMFNIZWw0MXJkUzhEcTRWSzdoRTRvLTJvYUx6R2VqU3RfZFhSLXFIaTRXYXRnSEVMaS10d0JLZE5QQzkzOG55elBvR0ROX3pR?oc=5" target="_blank">Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels</a>  <font color="#6f6f6f">Rockefeller University Press</font>

Read Full StoryMore like this
CXCR4- modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies
Naturegeneral

CXCR4- modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE94MEdCV3Zjanc3S181Ql9jdTNpdmluMExHanhlTU4xM1NURVZndWhTRkhzM1F6UHhreVFNWG5SSXlNY2lUeWpVZng2NlVXMERVVTdrQmRNVmJuaXBQR0ZN?oc=5" target="_blank">CXCR4- modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"BCMA/CD19 CAR T Shows Enc" — Live Google News Trends & Headlines